RecruitingPhase 4NCT07818707

Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)


Sponsor

Joslin Diabetes Center

Enrollment

40 participants

Start Date

Jan 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, the investigators will determine (a) whether metabolism (secretion and turnover) of glucagon is altered in patients with PBH, (b) whether this is affected by a meal, (c) whether PBH affects the ability of the body to produce glucose (endogenous glucose production), and (d) whether PBH affects the amount of glycogen in the liver (storage form of glucose) when fasting and after a meal. The investigators will determine the effect of glucagon to raise glucose levels after a meal. To answer these questions, participants will receive an infusion of a stable (nonradioactive) isotope of glucose and glucagon, and a meal containing a stable isotope of glucose. Glycogen will be measured by magnetic resonance imaging (MRI) of the liver before and after the meal. This information will be used to develop computer models for the glucagon pump system.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Glucagon for Injection (Fresenius Kabi USA), a drug called [1-13C] glucose, and others for people with bariatric surgery, hypoglycemia, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGlucagon for Injection (Fresenius Kabi USA)

The investigators are assessing glucagon metabolism in individuals with and without PBH in fasting and post-prandial states.

DRUG[6,6-2H2] glucose

The investigators are using a stable isotope glucose tracer to assess glucose metabolism in individuals with and without PBH in fasting and post-prandial states.

DRUG[13C9, 15N1]-glucagon

The investigators are assessing the metabolism of glucagon in individuals with and without PBH in fasting and post-prandial states.

DRUG[1-13C] glucose

The investigators are assessing the metabolism of glucose in individuals with and without PBH in fasting and post-prandial states.

DRUG[2-13C] glucose

The investigators assessing the metabolism of glucose in individuals with and without PBH in fasting and post-prandial states.


Locations(2)

University of Alabama

Birmingham, Alabama, United States

Joslin Diabetes Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07818707


Related Trials